The use of statins in childhood

Research output: Contribution to journalArticle

Abstract

Numerous studies have demonstrated the remarkable efficacy and safety of statins for the prevention of cardiovascular disease in high-risk adults. Currently statins are the most widely prescribed drug in the United States. Statins have been studied in randomized controlled trials in adolescents with severe Familial Hypercholesterolemia and short-term studies verify that they are effective at lowering LDL cholesterol and improve surrogate markers of atherosclerosis. They appear safe over the short term. Interest is growing in their use in adolescents at high risk of future cardiovascular disease however many questions remain unanswered regarding their use, including the optimal timing of their introduction, the safety of their long-term use and whether we should prescribe low does statins or escalate doses to achieve a target level of LDL-cholesterol. The purpose of the paper is to review what is known about statins and to highlight particular areas of uncertainty with respect to their use that I believe are often under appreciated and nonetheless important for pediatricians to know.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalPaediatria Croatica, Supplement
Volume53
Issue numberSUPPL. 1
StatePublished - 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Cardiovascular Diseases
Safety
Hyperlipoproteinemia Type II
Uncertainty
Atherosclerosis
Randomized Controlled Trials
Biomarkers
Pharmaceutical Preparations

Keywords

  • Familial hyperlipoproteinemia type II
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Primary prevention

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The use of statins in childhood. / Belamarich, Peter F.

In: Paediatria Croatica, Supplement, Vol. 53, No. SUPPL. 1, 2009, p. 1-6.

Research output: Contribution to journalArticle

@article{8d4d2b8c06a84bc788a50da9ac8fb252,
title = "The use of statins in childhood",
abstract = "Numerous studies have demonstrated the remarkable efficacy and safety of statins for the prevention of cardiovascular disease in high-risk adults. Currently statins are the most widely prescribed drug in the United States. Statins have been studied in randomized controlled trials in adolescents with severe Familial Hypercholesterolemia and short-term studies verify that they are effective at lowering LDL cholesterol and improve surrogate markers of atherosclerosis. They appear safe over the short term. Interest is growing in their use in adolescents at high risk of future cardiovascular disease however many questions remain unanswered regarding their use, including the optimal timing of their introduction, the safety of their long-term use and whether we should prescribe low does statins or escalate doses to achieve a target level of LDL-cholesterol. The purpose of the paper is to review what is known about statins and to highlight particular areas of uncertainty with respect to their use that I believe are often under appreciated and nonetheless important for pediatricians to know.",
keywords = "Familial hyperlipoproteinemia type II, Hydroxymethylglutaryl-CoA reductase inhibitors, Primary prevention",
author = "Belamarich, {Peter F.}",
year = "2009",
language = "English (US)",
volume = "53",
pages = "1--6",
journal = "Paediatria Croatica, Supplement",
issn = "1330-724X",
publisher = "Children's Hospital Zagreb",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The use of statins in childhood

AU - Belamarich, Peter F.

PY - 2009

Y1 - 2009

N2 - Numerous studies have demonstrated the remarkable efficacy and safety of statins for the prevention of cardiovascular disease in high-risk adults. Currently statins are the most widely prescribed drug in the United States. Statins have been studied in randomized controlled trials in adolescents with severe Familial Hypercholesterolemia and short-term studies verify that they are effective at lowering LDL cholesterol and improve surrogate markers of atherosclerosis. They appear safe over the short term. Interest is growing in their use in adolescents at high risk of future cardiovascular disease however many questions remain unanswered regarding their use, including the optimal timing of their introduction, the safety of their long-term use and whether we should prescribe low does statins or escalate doses to achieve a target level of LDL-cholesterol. The purpose of the paper is to review what is known about statins and to highlight particular areas of uncertainty with respect to their use that I believe are often under appreciated and nonetheless important for pediatricians to know.

AB - Numerous studies have demonstrated the remarkable efficacy and safety of statins for the prevention of cardiovascular disease in high-risk adults. Currently statins are the most widely prescribed drug in the United States. Statins have been studied in randomized controlled trials in adolescents with severe Familial Hypercholesterolemia and short-term studies verify that they are effective at lowering LDL cholesterol and improve surrogate markers of atherosclerosis. They appear safe over the short term. Interest is growing in their use in adolescents at high risk of future cardiovascular disease however many questions remain unanswered regarding their use, including the optimal timing of their introduction, the safety of their long-term use and whether we should prescribe low does statins or escalate doses to achieve a target level of LDL-cholesterol. The purpose of the paper is to review what is known about statins and to highlight particular areas of uncertainty with respect to their use that I believe are often under appreciated and nonetheless important for pediatricians to know.

KW - Familial hyperlipoproteinemia type II

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=82455216842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455216842&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:82455216842

VL - 53

SP - 1

EP - 6

JO - Paediatria Croatica, Supplement

JF - Paediatria Croatica, Supplement

SN - 1330-724X

IS - SUPPL. 1

ER -